In yesterday’s Wall Street session, Roivant Sciences Ltd. (NASDAQ:ROIV) shares traded at $10.81, down -1.46% from the previous session.
As of this writing, 9 analysts cover Roivant Sciences Ltd. (NASDAQ:ROIV). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $23.00 and a low of $12.00, we find $15.00. Given the previous closing price of $10.97, this indicates a potential upside of 36.74 percent. ROIV stock price is now 1.28% away from the 50-day moving average and 28.20% away from the 200-day moving average. The market capitalization of the company currently stands at $8.18B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
There are 1 analysts who have given it a hold rating, whereas 8 have given it a buy rating. Brokers who have rated the stock have averaged $15.88 as their price target over the next twelve months.
With the price target of $10.50, BofA Securities recently initiated with Neutral rating for Roivant Sciences Ltd. (NASDAQ: ROIV).
In other news, Venker Eric, Chief Operating Officer sold 59,811 shares of the company’s stock on Aug 14. The stock was sold for $711,153 at an average price of $11.89. Upon completion of the transaction, the Chief Operating Officer now directly owns 627,918 shares in the company, valued at $6.79 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 03, Chief Operating Officer Venker Eric sold 44,629 shares of the business’s stock. A total of $532,424 was realized by selling the stock at an average price of $11.93. This leaves the insider owning 627,918 shares of the company worth $6.79 million. A total of 14.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ROIV stock. A new stake in Roivant Sciences Ltd. shares was purchased by AVORO CAPITAL ADVISORS LLC during the first quarter worth $62,765,000. FARALLON CAPITAL MANAGEMENT LLC invested $25,458,000 in shares of ROIV during the first quarter. In the first quarter, LOOMIS SAYLES & CO L P acquired a new stake in Roivant Sciences Ltd. valued at approximately $21,193,000. AVIDITY PARTNERS MANAGEMENT LP acquired a new stake in ROIV for approximately $18,242,000. DECHENG CAPITAL MANAGEMENT III (CAYMAN), LLC purchased a new stake in ROIV valued at around $15,779,000 in the second quarter. In total, there are 211 active investors with 51.20% ownership of the company’s stock.
Wednesday morning saw Roivant Sciences Ltd. (NASDAQ: ROIV) opened at $10.93. During the past 12 months, Roivant Sciences Ltd. has had a low of $2.87 and a high of $12.01. As of last week, the company has a debt-to-equity ratio of 0.36, a current ratio of 6.60, and a quick ratio of 6.60. The fifty day moving average price for ROIV is $10.70 and a two-hundred day moving average price translates $8.46 for the stock.
The latest earnings results from Roivant Sciences Ltd. (NASDAQ: ROIV) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.38, missing analysts’ expectations of -$0.3 by -0.08. This compares to -$0.51 EPS in the same period last year. The company reported revenue of $21.62 million for the quarter, compared to $4.32 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 400.67 percent. For the current quarter, analysts expect ROIV to generate $30.55M in revenue.
Roivant Sciences Ltd.(ROIV) Company Profile
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn’s disease. The company was founded in 2014 and is based in London, the United Kingdom.
